How Sun Pharma integrates its business will be keenly followed, says Kohli. Merged entity will take some time to derive synergistic benefits, he adds.from Stocks-Markets-The Economic Times http://ift.tt/1A88DXO
Monday, 9 March 2015
Sun Pharma-Ranbaxy merger may put pressure on Ebitda margins of merged entity: Daljeet Singh Kohli
How Sun Pharma integrates its business will be keenly followed, says Kohli. Merged entity will take some time to derive synergistic benefits, he adds.from Stocks-Markets-The Economic Times http://ift.tt/1A88DXO
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment